Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation

References

• Greene P. Outpatient Drug Utilization Trends for Buprenorphine Years 2002–2009. FDA Office of Surveillance and Epidemiology. 2010. Presentation Archived by WebCite^®. Available from: http://www.webcitation.org/6OJVKGwyg Accessed October 15, 2019.
   Google Scholar
• Fiellin DA. The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med. 2007;1(2):62–67. doi:10.1097/ADM.0b013e3180473c1121768936
   PubMed Web of Science ®Google Scholar
• Ling W. A perspective on opioid pharmacotherapy: where we are and how we got here. J Neuroimmune Pharm. 2016;11(3):394–400. doi:10.1007/s11481-016-9663-z
   Web of Science ®Google Scholar
• Ling W. Buprenorphine for opioid dependence. Expert Rev Neurother. 2009;9(5):609–616. doi:10.1586/ern.09.2619402772
   PubMed Web of Science ®Google Scholar
• Lugoboni F, Zamboni L, Cibin M, Tamburin S; Gruppo Inter SdCS. Intravenous misuse of methadone, buprenorphine and buprenorphine-naloxone in patients under opioid maintenance treatment: a cross-sectional multicentre study. Eur Addict Res. 2019;25(1):10–19. doi:10.1159/00049611230625491
   PubMed Web of Science ®Google Scholar
• Moratti E, Kashanpour H, Lombardelli T, Maisto M. Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy. Clin Drug Investig. 2010;30 Suppl 1:3–11. doi:10.2165/11536020-000000000-00000
   Web of Science ®Google Scholar
• Webster LR, Smith MD, Unal C, Finn A. Low-dose naloxone provides an abuse-deterrent effect to buprenorphine. J Pain Res. 2015;8:791–798. doi:10.2147/JPR.S9078026604818
   PubMed Web of Science ®Google Scholar
• White J, Bell J, Saunders JB, et al. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend. 2009;103(1–2):37–43. doi:10.1016/j.drugalcdep.2009.03.00819403243
   PubMed Web of Science ®Google Scholar
• Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA. 2010;304(14):1576–1583. doi:10.1001/jama.2010.142720940383
   PubMed Web of Science ®Google Scholar
• Rosenthal RN, Ling W, Casadonte P, et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction. 2013;108(12):2141–2149. doi:10.1111/add.1231523919595
   PubMed Web of Science ®Google Scholar
• Administration FD. PROBUPHINE (buprenorphine) implant for subdermal administration CIII. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204442Orig1s000lbl.pdf Published 2016 Accessed 310, 2019.
   Google Scholar
• Neale J, Tompkins CNE, Strang J. Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations. Harm Reduct J. 2019;16(1):25. doi:10.1186/s12954-019-0296-430943990
   PubMed Web of Science ®Google Scholar
• Neale J, Tompkins CNE, McDonald R, Strang J. Implants and depot injections for treating opioid dependence: qualitative study of people who use or have used heroin. Drug Alcohol Depend. 2018;189:1–7. doi:10.1016/j.drugalcdep.2018.03.05729857327
   PubMed Web of Science ®Google Scholar
• Alderks CE. Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003–2015 (update) In: The CBHSQ Report. Rockville, MD: Substance Abuse and Mental Health Services Administration (US); 2013:1–8.
   Google Scholar
• Dunn R. The atrigel drug delivery system. In: Rathbone M, Hadgraft J, Editors Modified-Release Drug Delivery Technology. Boca Raton, FL: CRC Press; 2002.
   Google Scholar
• Laffont CM, Gomeni R, Heidbreder C, Jones JP 3rd, Nasser AF. Population pharmacokinetic modeling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder. J Clin Pharmacol. 2016;56(7):806–815. doi:10.1002/jcph.66526479717
   PubMed Web of Science ®Google Scholar
• Nasser AF, Greenwald MK, Vince B, et al. Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder. J Clin Psychopharmacol. 2016;36(1):18–26. doi:10.1097/JCP.000000000000043426650971
   PubMed Web of Science ®Google Scholar
• Haight BR, Learned SM, Laffont CM, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019;393(10173):778–790. doi:10.1016/S0140-6736(18)32259-130792007
   PubMed Web of Science ®Google Scholar
• Hertz S Approval package for: SUBLOCADE extended-release injection for subcutaneous use, 100 and 300 mg. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209819Orig1s000Approv.pdf Published 2017 Accessed 1010, 2019.
   Google Scholar
• Hertz S Tentative approval of BRIXADI. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210136Orig1s000TALtr.pdf Published 2018 Accessed 1010, 2019.
   Google Scholar
• Albayaty M, Linden M, Olsson H, Johnsson M, Strandgarden K, Tiberg F. Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label Phase 1 study. Adv Ther. 2017;34(2):560–575. doi:10.1007/s12325-016-0472-928070862
   PubMed Web of Science ®Google Scholar
• Frost M, Bailey GL, Lintzeris N, et al. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Addiction. 2019;114(8):1416–1426. doi:10.1111/add.1463631013390
   PubMed Web of Science ®Google Scholar
• Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018;178(6):764–773. doi:10.1001/jamainternmed.2018.105229799968
   PubMed Web of Science ®Google Scholar
• Mendoza S, Rivera-Cabrero AS, Hansen H. Shifting blame: buprenorphine prescribers, addiction treatment, and prescription monitoring in middle-class America. Transcult Psychiatry. 2016;53(4):465–487. doi:10.1177/136346151666088427488225
   PubMed Web of Science ®Google Scholar
• Gilman M, Li L, Hudson K, et al. Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine. Patient Prefer Adherence. 2018;12:2123–2129. doi:10.2147/PPA.S18064130349206
   PubMed Web of Science ®Google Scholar
• Neale J, Tompkins CNE, Strang J. Depot buprenorphine injections for opioid use disorder: patient information needs and preferences. Drug Alcohol Rev. 2019;38(5):510–518. doi:10.1111/dar.1293931131514
   PubMed Web of Science ®Google Scholar
• Tompkins CNE, Neale J, Strang J. Opioid users’ willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder. J Subst Abuse Treat. 2019;104:64–71. doi:10.1016/j.jsat.2019.06.00731370986
   PubMed Web of Science ®Google Scholar
• Preston KL, Kowalczyk WJ, Phillips KA, et al. Before and after: craving, mood, and background stress in the hours surrounding drug use and stressful events in patients with opioid-use disorder. Psychopharmacology (Berl). 2018;235(9):2713–2723. doi:10.1007/s00213-018-4966-929980821
   PubMed Web of Science ®Google Scholar
• Ray LA, Lim AC, Shoptaw S. What defines a clinically meaningful outcome in the treatment of substance use disorders: ‘Getting your life back’. Addiction. 2019;114(1):18–20. doi:10.1111/add.v114.130426617
   PubMed Web of Science ®Google Scholar
• Ling W. Mastering the Addicted Brain: Building a Sane and Meaningful Life to Stay Clean. Novato, CA: New World Library; 2017.
   Google Scholar
• Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90–96. doi:10.1016/j.jsat.2017.07.00128733097
   PubMed Web of Science ®Google Scholar
• Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction. 2013;108(10):1788–1798. doi:10.1111/add.1226623734858
   PubMed Web of Science ®Google Scholar
• Burns RM, Pacula RL, Bauhoff S, et al. Policies related to opioid agonist therapy for opioid use disorders: the evolution of state policies from 2004 to 2013. Subst Abus. 2016;37(1):63–69. doi:10.1080/08897077.2015.108020826566761
   PubMed Web of Science ®Google Scholar
• Nowotny KM. Race/ethnic disparities in the utilization of treatment for drug dependent inmates in U.S. state correctional facilities. Addict Behav. 2015;40:148–153. doi:10.1016/j.addbeh.2014.09.00525270722
   PubMed Web of Science ®Google Scholar
• Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci. 2007;9(4):455–470.18286804
   PubMedGoogle Scholar
• Juurlink DN. Lofexidine for opioid withdrawal: small effects at an exorbitant price. J Addict Med. 2019;13(3):167–168. doi:10.1097/ADM.000000000000047330531233
   PubMed Web of Science ®Google Scholar
• Hedegaard H, Miniño AM, Warner M. Drug Overdose Deaths in the United States, 1999–2017. Hyattsville, MD: National Center for Health Statistics; 2018.
   Google Scholar